Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
W Joost Lesterhuis, Joanne Salmons, Anna K Nowak, Esdy N Rozali, Andrea Khong, Ian M Dick, Julie A Harken, Bruce W Robinson, Richard A Lake, W Joost Lesterhuis, Joanne Salmons, Anna K Nowak, Esdy N Rozali, Andrea Khong, Ian M Dick, Julie A Harken, Bruce W Robinson, Richard A Lake
Abstract
Several chemotherapeutics exert immunomodulatory effects. One of these is the nucleoside analogue gemcitabine, which is widely used in patients with lung cancer, ovarian cancer, breast cancer, mesothelioma and several other types of cancer, but with limited efficacy. We hypothesized that the immunopotentiating effects of this drug are partly restrained by the inhibitory T cell molecule CTLA-4 and thus could be augmented by combining it with a blocking antibody against CTLA-4, which on its own has recently shown beneficial clinical effects in the treatment of patients with metastatic melanoma. Here we show, using two non-immunogenic murine tumor models, that treatment with gemcitabine chemotherapy in combination with CTLA-4 blockade results in the induction of a potent anti-tumor immune response. Depletion experiments demonstrated that both CD4(+) and CD8(+) T cells are required for optimal therapeutic effect. Mice treated with the combination exhibited tumor regression and long-term protective immunity. In addition, we show that the efficacy of the combination is moderated by the timing of administration of the two agents. Our results show that immune checkpoint blockade and cytotoxic chemotherapy can have a synergistic effect in the treatment of cancer. These results provide a basis to pursue combination therapies with anti-CTLA-4 and immunopotentiating chemotherapy and have important implications for future studies in cancer patients. Since both drugs are approved for use in patients our data can be immediately translated into clinical trials.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy - revisited. Nat Rev Drug Discov 10: 591–600.
- Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer 5: 397–405.
- Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54–61.
- Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, et al. (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120: 1111–1124.
- Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, et al. (2011) Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 121: 3100–3108.
- Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62: 2353–2358.
- Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, et al. (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170: 4905–4913.
- Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102: 115–123.
- Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, et al. (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71: 5101–5110.
- Rettig L, Seidenberg S, Parvanova I, Samaras P, Knuth A, et al. (2011) Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 129: 832–838.
- Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58: 823–830.
- Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
- Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, et al... (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med.
- Pedicord VA, Montalvo W, Leiner IM, Allison JP (2011) Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 108: 266–271.
- Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490–4496.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al... (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med.
- Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, et al. (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30: 1147–1158.
- Fu T, He Q, Sharma P (2011) The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71: 5445–5454.
- Liakou CI, Kamat A, Tang DN, Chen H, Sun J, et al. (2008) CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105: 14987–14992.
- Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, et al... (2012) Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. J Clin Oncol.
- Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, et al. (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 29: 489–498.
- Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA (1998) Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 58: 5301–5304.
- Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M (2012) CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther.
- Chakraborty M, Schlom J, Hodge JW (2007) The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother 56: 1471–1484.
- Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, et al. (2004) CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22: 1700–1708.
Source: PubMed